SLC50A1 inhibits the doxorubicin sensitivity in hepatocellular carcinoma cells through regulating the tumor glycolysis
2024

SLC50A1 and Its Role in Liver Cancer

Sample size: 15 publication 10 minutes Evidence: high

Author Information

Author(s): Wang Ganggang, Jin Wenzhi, Zhang Lianmei, Dong Meiyuan, Zhang Xin, Zhou Zhijie

Primary Institution: Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Shanghai, China

Hypothesis

This study aims to investigate the function and underlying mechanisms of SLC50A1 in the occurrence and progression of hepatocellular carcinoma (HCC).

Conclusion

The study identifies the METTL3/SLC50A1 axis as a novel therapeutic target in the context of hepatocellular carcinoma.

Supporting Evidence

  • SLC50A1 is significantly upregulated in liver cancer compared to normal tissues.
  • Overexpression of SLC50A1 predicts unfavorable prognosis in liver cancer patients.
  • SLC50A1 enhances resistance of HCC cells to Doxorubicin (DOX) and 2-deoxy-D-glucose (2-DG).
  • Downregulation of SLC50A1 inhibits liver cancer cell growth by inducing G1 cell cycle arrest.
  • SLC50A1 regulates cellular glycolysis and the cell cycle, promoting tumorigenesis.

Takeaway

SLC50A1 is a protein that helps liver cancer cells grow and resist treatment, making it a potential target for new therapies.

Methodology

The study utilized bioinformatics analysis, clinical sample testing, in vitro and in vivo experiments to assess SLC50A1 expression and its effects on HCC.

Participant Demographics

15 HCC patients with clinical samples collected.

Statistical Information

P-Value

p<0.001

Statistical Significance

p<0.001

Digital Object Identifier (DOI)

10.1038/s41420-024-02261-3

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication